Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010707 · ClinicalTrials.gov registry record · Phase 2
Transgender Estradiol Affirming Therapy
A Phase 2 study of Transgenderism, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05010707 is a Phase 2 study of Transgenderism that has completed, run by Washington University School of Medicine. The registered enrollment target is 39 participants, below the 62-participant average among 5 other Transgenderism trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05010707, a Phase 2 study of Transgenderism, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.
Conditions Studied
Interventions
- DRUG Transdermal patch
- DIAGNOSTIC_TEST Pro-thrombotic markers
- DIAGNOSTIC_TEST Metabolic markers
- DIAGNOSTIC_TEST Hormone Profile
- DRUG Daily Sublingual Tablet
Study Locations (1)
Missouri
- Washington University Transgender Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05010707
The ClinicalTrials.gov registry entry for NCT05010707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 5 other Transgenderism trials with a reported enrollment target (37% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transgenderism appearing as the primary indexed condition, and to 5 interventions - of which Transdermal patch is the first listed.
NCT05010707 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05010707 about?
NCT05010707 is a clinical study titled "Transgender Estradiol Affirming Therapy". The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.
What is the current status of trial NCT05010707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2021-08-02. Estimated completion is 2024-01-01.
What conditions does trial NCT05010707 study?
This clinical trial studies the following conditions: Transgenderism.
What interventions are being tested in trial NCT05010707?
The interventions under investigation include: Transdermal patch (DRUG), Pro-thrombotic markers (DIAGNOSTIC_TEST), Metabolic markers (DIAGNOSTIC_TEST), Hormone Profile (DIAGNOSTIC_TEST), Daily Sublingual Tablet (DRUG).
Who is sponsoring clinical trial NCT05010707?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010707 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transgenderism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puberty Suppression and Cardiometabolic Health
RECRUITING
-
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
RECRUITING · Phase 4
-
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
RECRUITING
-
Cardiometabolic Health in Transgender Males
ACTIVE NOT RECRUITING
-
Effect of Hormone Therapy on Renal Function
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.